


# CLAIMS

- 1) (Currently Amended) Compounds of formula (I), (Ia) and (Ib)



wherein:

A is N,

B is selected from C-Y and N,

R<sup>1</sup> is selected from H and (C<sub>1</sub>-C<sub>6</sub>)alkyl,

R<sup>2</sup> is selected from H and (C<sub>1</sub>-C<sub>6</sub>)alkyl,

~~X is selected from H, HO, C(O)NH<sub>2</sub>, NH<sub>2</sub>,~~

Y is selected from H, HO, NH<sub>2</sub>, Br, Cl and F,

Z is selected from H, HO, F, CONH<sub>2</sub> and CN;

~~and or pharmaceutically acceptable salts, and solvates and prodrugs thereof.~~

2. (Previously Presented) Compounds of formula (I), (Ia) and (Ib) as claimed in claim 1 wherein A is N and B is C-Y.

3. (Previously presented) Compounds of formula (I), (Ia) and (Ib) as claimed in claims 1 or 2 wherein R<sup>1</sup> is H, methyl and ethyl.

4. (Currently amended) Compounds of formula (I), (Ia) and (Ib) as claimed in claims 1 or 2 wherein R<sup>2</sup> is selected from H and methyl.

5. (Cancelled).

6. (Previously presented) Compounds of formula (I), (Ia) and (Ib) as claimed in claims 1 or 2 wherein Y is selected from H, NH<sub>2</sub>, Cl and F.

7. (Previously presented) Compounds of formula (I), (Ia) and (Ib) as claimed in claims 1 or 2 wherein Z is selected from H, HO and F.

8. (Currently Amended) A compound selected from

~~5-(4-Propylmorpholin-2-yl)pyridin-2-ylamine;~~

5-[(2S,5S)-5-methyl-4-propylmorpholin-2-yl]pyridin-2-amine and

5-[(2R,5S)-5-methyl-4-propylmorpholin-2-yl]pyridin-2-amine.

9) (Cancelled).

10) (Withdrawn) A method of treating sexual dysfunction, female sexual dysfunction, including hypoactive sexual desire disorder, sexual arousal disorder, orgasmic disorder and sexual pain disorder; male erectile dysfunction, hypertension, neurodegeneration, psychiatric disorders, depression, generalized anxiety disorder, phobias, posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's diseases, endocrine disorders, vasospasm, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention deficit hyperactivity disorder, chronic paroxysmal hemicrania, headache associated with vascular disorders, emotional lability, pathological crying, sleeping disorder and shock comprising administering a therapeutically effective amount of a compound as claimed in claims 1 or 8 to a patient in need of treatment thereof.

11. (Withdrawn) A method as recited in claim 10 where the condition is female sexual dysfunction, male erectile dysfunction, neurodegeneration, depression and psychiatric disorders.


12. (Withdrawn) A method as recited in claim 10 where the condition is male erectile dysfunction

13. (Withdrawn) A method as recited in claim 10 where the condition is hypoactive sexual desire disorder, sexual arousal disorder, orgasmic disorder and sexual pain disorder in females.

14. (Withdrawn) A method as recited in claim 13 where the condition is female sexual arousal disorder and concomitant hypoactive sexual desire disorder.


15. (Withdrawn) A composition containing a compound of formula (I), (Ia) or (Ib) as recited in claim 1 or 8 and a pharmaceutically acceptable diluent or carrier.

16. (Currently Amended) A compound of formula (Ia),



a pharmaceutically acceptable salt thereof, ~~a prodrug of the compound or the salt~~, or a solvate of the compound or, salt ~~or prodrug~~.

17. (Currently Amended) Compounds of formula (I), (Ia) and (Ib)



wherein:

A is selected from C-X and N,

B is N,

R<sup>1</sup> is selected from H and (C<sub>1</sub>-C<sub>6</sub>)alkyl,

R<sup>2</sup> is selected from H and (C<sub>1</sub>-C<sub>6</sub>)alkyl,


X is selected from H, HO, C(O)NH<sub>2</sub>, NH<sub>2</sub>,

Y is selected from H, HO, NH<sub>2</sub>, Br, Cl and F,

Z is selected from H, HO, F, CONH<sub>2</sub> and CN;

or and pharmaceutically acceptable salts, and solvates ~~and prodrugs~~ thereof.

18. (New) Compounds of formula (I), (Ia) and (Ib)



wherein:

A is N,

B is selected from C-Y and N;

R<sup>1</sup> is (C<sub>1</sub>-C<sub>6</sub>)alkyl;

R<sup>2</sup> is H;

Y is selected from H, HO, NH<sub>2</sub>, Br, Cl and F,

Z is selected from H, HO, F, CONH<sub>2</sub> and CN;

or pharmaceutically acceptable salts and solvates thereof.

19. (New) Compounds of formula (I), (Ia) and (Ib) as claimed in claim 18 wherein B is C-Y.

20. (New) Compounds of formula (I), (Ia) and (Ib) as claimed in claims 18 or 19 wherein R<sup>1</sup> is methyl and ethyl.

21. (New) Compounds of formula (I), (Ia) and (Ib) as claimed in claims 18 or 19 wherein Y is selected from H, NH<sub>2</sub>, Cl and F.

22. (New) Compounds of formula (I), (Ia) and (Ib) as claimed in claims 18 or 19 wherein Z is selected from H, HO and F.